Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Accelerated TMS for Apathy in PD

NCT: NCT07399496 · RECRUITING

NCT IDNCT07399496
StatusRECRUITING
Start Date2026-06-01
Completion2027-03-01

Brief Summary

This single-site, open-label pilot study will evaluate the feasibility, tolerability, and preliminary efficacy of accelerated intermittent theta-burst stimulation (iTBS) targeting the dorsomedial prefrontal cortex (dmPFC) for apathy in individuals with Parkinson's Disease (PD). Fifteen participants with PD and clinically significant apathy will undergo six treatment visits over two weeks, receiving eight iTBS sessions per day. Outcomes include adherence, tolerability, changes in apathy (Lille Apathy Rating Scale), functional engagement, and neural target engagement assessed via resting-state fMRI and EEG. Follow-up assessments will occur at two and four weeks post-treatment.

Frequently Asked Questions

What is Accelerated TMS for Apathy in PD?

Accelerated TMS for Apathy in PD is a clinical trial registered under NCT07399496. Current status: RECRUITING.

What is the status of NCT07399496?

The current status of NCT07399496 (Accelerated TMS for Apathy in PD) is: RECRUITING.

When did Accelerated TMS for Apathy in PD start?

Accelerated TMS for Apathy in PD started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.